Constitutive Fms-like tyrosine kinase 3 activation results in specific changes in gene expression in myeloid leukaemic cells

British Journal of Haematology

Volumn 138, Issue 5, 2007, Pages 603-615

  Kim, Kyu Tae ^a,e   Baird, Kristin ^b   Davis, Sean ^b   Piloto, Obdulio ^a   Levis, Mark ^a   Li, Li ^a   Chen, Peili ^a   Meltzer, Paul ^b   Small, Donald ^a,c,d  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c Pediatric Oncology   (United States)

^d CRB 251 ^*  (United States)

^e UNIVERSITY OF NEWCASTLE   (Australia)

Author keywords

Acute myeloid leukaemia; Fms like tyrosine kinase 3; Fms like tyrosine kinase 3 internal tandem duplication; Gene expression profile

Indexed keywords

CD135 ANTIGEN; COMPLEMENTARY DNA; JANUS KINASE; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; RAS PROTEIN; STAT PROTEIN;

ARTICLE; CONTROLLED STUDY; DNA MICROARRAY; ENZYME ACTIVATION; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; LEUKEMOGENESIS; MYELOID LEUKEMIA; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

CELL PROLIFERATION; CYCLINS; DNA, COMPLEMENTARY; DNA, NEOPLASM; FMS-LIKE TYROSINE KINASE 3; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; LEUKEMIA, MYELOID; NEOPLASM PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS C-MYC; PROTO-ONCOGENE PROTEINS C-PIM-1; RNA, NEOPLASM; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 34547637587     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2007.06696.x     Document Type: Article

References (44)

1. Bai, M., Tsanou, E., Agnantis, N.J., Chaidos, A., Dimou, D., Skyrlas, A., Dimou, S., Vlychou, M., Galani, V. Kanavaros, P. (2003) Expression of cyclin D3 and cyclin E and identification of distinct clusters of proliferation and apoptosis in diffuse large B-cell lymphomas. Histology and Histopathology, 18, 449 457.
2. Birg, F., Courcoul, M., Rosnet, O., Bardin, F., Pebusque, M.J., Marchetto, S., Tabilio, A., Mannoni, P. Birnbaum, D. (1992) Expression of the FMS/KIT-like gene FLT3 in human acute leukemias of the myeloid and lymphoid lineages. Blood, 80, 2584 2593.
3. Blum, K.A., Lozanski, G. Byrd, J.C. (2004) Adult Burkitt leukemia and lymphoma. Blood, 104, 3009 3020.
4. Carow, C.E., Levenstein, M., Kaufmann, S.H., Chen, J., Amin, S., Rockwell, P., Witte, L., Borowitz, M.J., Civin, C.I. Small, D. (1996) Expression of the hematopoietic growth factor receptor FLT3 (STK-1/Flk2) in human leukemias. Blood, 87, 1089 1096.
5. Cleveland, J.L., Dean, M., Rosenberg, N., Wang, J.Y. Rapp, U.R. (1989) Tyrosine kinase oncogenes abrogate interleukin-3 dependence of murine myeloid cells through signaling pathways involving c-myc: conditional regulation of c-myc transcription by temperature-sensitive v-abl. Molecular and Cellular Biology, 9, 5685 5695.
6. DeRisi, J., Penland, L., Brown, P.O., Bittner, M.L., Meltzer, P.S., Ray, M., Chen, Y., Su, Y.A. Trent, J.M. (1996) Use of a cDNA microarray to analyse gene expression patterns in human cancer. Nature Genetics 14: 457 460.
7. Dhanasekaran, S.M., Barrette, T.R., Ghosh, D., Shah, R., Varambally, S., Kurachi, K., Pienta, K.J., Rubin, M.A. Chinnaiyan, A.M. (2001) Delineation of prognostic biomarkers in prostate cancer. Nature, 412, 822 826.
8. Fenski, R., Flesch, K., Serve, S., Mizuki, M., Oelmann, E., Kratz-Albers, K., Kienast, J., Leo, R., Schwartz, S., Berdel, W.E. Serve, H. (2000) Constitutive activation of FLT3 in acute myeloid leukaemia and its consequences for growth of 32D cells. British Journal of Haematology, 108, 322 330.
9. Gilliland, D.G. Griffin, J.D. (2002) The roles of FLT3 in hematopoiesis and leukemia. Blood, 100, 1532 1542.
10. Gorre, M.E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P.N. Sawyers, C.L. (2001) Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science, 293, 876 880.
11. Hayakawa, F., Towatari, M., Kiyoi, H., Tanimoto, M., Kitamura, T., Saito, H. Naoe, T. (2000) Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines. Oncogene, 19, 624 631.
12. Heidel, F., Solem, F.K., Breitenbuecher, F., Lipka, D.B., Kasper, S., Thiede, M.H., Brandts, C., Serve, H., Roesel, J., Giles, F., Feldman, E., Ehninger, G., Schiller, G.J., Nimer, S., Stone, R.M., Wang, Y., Kindler, T., Cohen, P.S., Huber, C. Fischer, T. (2006) Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain. Blood, 107, 293 300.
13. Kelly, L.M., Yu, J.C., Boulton, C.L., Apatira, M., Li, J., Sullivan, C.M., Williams, I., Amaral, S.M., Curley, D.P., Duclos, N., Neuberg, D., Scarborough, R.M., Pandey, A., Hollenbach, S., Abe, K., Lokker, N.A., Gilliland, D.G. Giese, N.A. (2002) CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML). Cancer Cell, 1, 421 432.
14. Khan, J., Simon, R., Bittner, M., Chen, Y., Leighton, S.B., Pohida, T., Smith, P.D., Jiang, Y., Gooden, G.C., Trent, J.M. Meltzer, P.S. (1998) Gene expression profiling of alveolar rhabdomyosarcoma with cDNA microarrays. Cancer Research, 58, 5009 5013.
15. Kim, K.T., Baird, K., Ahn, J.Y., Meltzer, P., Lilly, M., Levis, M. Small, D. (2005) Pim-1 is up-regulated by constitutively activated FLT3 and plays a role in FLT3-mediated cell survival. Blood, 105, 1759 1767.
16. Kiyoi, H., Towatari, M., Yokota, S., Hamaguchi, M., Ohno, R., Saito, H. Naoe, T. (1998) Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product. Leukemia, 12, 1333 1337.
17. Levis, M. Small, D. (2003) FLT3: ITDoes matter in leukemia. Leukemia, 17, 1738 1752.
18. Levis, M. Small, D. (2004) Small molecule FLT3 tyrosine kinase inhibitors. Current Pharmaceutical Design, 10, 1183 1193.
19. Levis, M., Tse, K.F., Smith, B.D., Garrett, E. Small, D. (2001) A FLT3 tyrosine kinase inhibitor is selectively cytotoxic to acute myeloid leukemia blasts harboring FLT3 internal tandem duplication mutations. Blood, 98, 885 887.
20. Levis, M., Allebach, J., Tse, K.F., Zheng, R., Baldwin, B.R., Smith, B.D., Jones-Bolin, S., Ruggeri, B., Dionne, C. Small, D. (2002) A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo. Blood, 99, 3885 3891.
21. Levis, M., Pham, R., Smith, B.D. Small, D. (2004) In vitro studies of a FLT3 inhibitor combined with chemotherapy: sequence of administration is important to achieve synergistic cytotoxic effects. Blood, 104, 1145 1150.
22. Levy-Nissenbaum, O., Sagi-Assif, O., Kapon, D., Hantisteanu, S., Burg, T., Raanani, P., Avigdor, A., Ben-Bassat, I. Witz, I.P. (2003a) Dual-specificity phosphatase Pyst2-L is constitutively highly expressed in myeloid leukemia and other malignant cells. Oncogene, 22, 7649 7660.
23. Levy-Nissenbaum, O., Sagi-Assif, O., Raanani, P., Avigdor, A., Ben-Bassat, I. Witz, I.P. (2003b) Overexpression of the dual-specificity MAPK phosphatase PYST2 in acute leukemia. Cancer Letters, 199, 185 192.
24. Lilly, M., Le, T., Holland, P. Hendrickson, S.L. (1992) Sustained expression of the pim-1 kinase is specifically induced in myeloid cells by cytokines whose receptors are structurally related. Oncogene, 7, 727 732.
25. Lyman, S.D. Jacobsen, S.E. (1998) c-kit ligand and Flt3 ligand: stem/progenitor cell factors with overlapping yet distinct activities. Blood, 91, 1101 1134.
26. Mackarehtschian, K., Hardin, J.D., Moore, K.A., Boast, S., Goff, S.P. Lemischka, I.R. (1995) Targeted disruption of the flk2/flt3 gene leads to deficiencies in primitive hematopoietic progenitors. Immunity, 3, 147 161.
27. Mizuki, M., Fenski, R., Halfter, H., Matsumura, I., Schmidt, R., Muller, C., Gruning, W., Kratz-Albers, K., Serve, S., Steur, C., Buchner, T., Kienast, J., Kanakura, Y., Berdel, W.E. Serve, H. (2000) Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways. Blood, 96, 3907 3914.
28. Mizuki, M., Schwable, J., Steur, C., Choudhary, C., Agrawal, S., Sargin, B., Steffen, B., Matsumura, I., Kanakura, Y., Bohmer, F.D., Muller-Tidow, C., Berdel, W.E. Serve, H. (2003) Suppression of myeloid transcription factors and induction of STAT response genes by AML-specific Flt3 mutations. Blood, 101, 3164 3173.
29. Nakao, M., Yokota, S., Iwai, T., Kaneko, H., Horiike, S., Kashima, K., Sonoda, Y., Fujimoto, T. Misawa, S. (1996) Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia, 10, 1911 1918.
30. Piloto, O., Wright, M., Brown, P., Kim, K.T., Levis, M. Small, D. (2007) Prolonged exposure to FLT3 inhibitors leads to resistance via activation of parallel signaling pathways. Blood, 109, 1643 1652.
31. Rosnet, O. Birnbaum, D. (1993) Hematopoietic receptors of class III receptor-type tyrosine kinases. Critical Reviews in Oncogenesis, 4, 595 613.
32. Ross, M.E., Mahfouz, R., Onciu, M., Liu, H.C., Zhou, X., Song, G., Shurtleff, S.A., Pounds, S., Cheng, C., Ma, J., Ribeiro, R.C., Rubnitz, J.E., Girtman, K., Williams, W.K., Raimondi, S.C., Liang, D.C., Shih, L.Y., Pui, C.H. Downing, J.R. (2004) Gene expression profiling of pediatric acute myelogenous leukemia. Blood, 104, 3679 3687.
33. Schultheis, B., Carapeti-Marootian, M., Hochhaus, A., Weisser, A., Goldman, J.M. Melo, J.V. (2002) Overexpression of SOCS-2 in advanced stages of chronic myeloid leukemia: possible inadequacy of a negative feedback mechanism. Blood, 99, 1766 1775.
34. Stirewalt, D.L. Radich, J.P. (2003) The role of FLT3 in haematopoietic malignancies. Nature Reviews Cancer, 3, 650 665.
35. Tse, K.F., Mukherjee, G. Small, D. (2000) Constitutive activation of FLT3 stimulates multiple intracellular signal transducers and results in transformation. Leukemia, 14, 1766 1776.
36. Tse, K.F., Novelli, E., Civin, C.I., Bohmer, F.D. Small, D. (2001) Inhibition of FLT3-mediated transformation by use of a tyrosine kinase inhibitor. Leukemia, 15, 1001 1010.
37. Tse, K.F., Allebach, J., Levis, M., Smith, B.D., Bohmer, F.D. Small, D. (2002) Inhibition of the transforming activity of FLT3 internal tandem duplication mutants from AML patients by a tyrosine kinase inhibitor. Leukemia, 16, 2027 2036.
38. Valk, P.J., Verhaak, R.G., Beijen, M.A., Erpelinck, C.A., Barjesteh van Waalwijk van Doorn-Khosrovani, S., Boer, J.M., Beverloo, H.B., Moorhouse, M.J., van der Spek, P.J., Lowenberg, B. Delwel, R. (2004) Prognostically useful gene-expression profiles in acute myeloid leukemia. New England Journal of Medicine, 350, 1617 1628.
39. Weisberg, E., Boulton, C., Kelly, L.M., Manley, P., Fabbro, D., Meyer, T., Gilliland, D.G. Griffin, J.D. (2002) Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. Cancer Cell, 1, 433 443.
40. Yamamoto, Y., Kiyoi, H., Nakano, Y., Suzuki, R., Kodera, Y., Miyawaki, S., Asou, N., Kuriyama, K., Yagasaki, F., Shimazaki, C., Akiyama, H., Saito, K., Nishimura, M., Motoji, T., Shinagawa, K., Takeshita, A., Saito, H., Ueda, R., Ohno, R. Naoe, T. (2001) Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood, 97, 2434 2439.
41. Yee, K.W., O'Farrell, A.M., Smolich, B.D., Cherrington, J.M., McMahon, G., Wait, C.L., McGreevey, L.S., Griffith, D.J. Heinrich, M.C. (2002) SU5416 and SU5614 inhibit kinase activity of wild-type and mutant FLT3 receptor tyrosine kinase. Blood, 100, 2941 2949.
42. Yokota, S., Kiyoi, H., Nakao, M., Iwai, T., Misawa, S., Okuda, T., Sonoda, Y., Abe, T., Kahsima, K., Matsuo, Y. Naoe, T. (1997) Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines. Leukemia, 11, 1605 1609.
43. Zheng, R., Levis, M., Piloto, O., Brown, P., Baldwin, B.R., Gorin, N.C., Beran, M., Zhu, Z., Ludwig, D., Hicklin, D., Witte, L., Li, Y. Small, D. (2004a) FLT3 ligand causes autocrine signaling in acute myeloid leukemia cells. Blood, 103, 267 274.
44. Zheng, R., Friedman, A.D., Levis, M., Li, L., Weir, E.G. Small, D. (2004b) Internal tandem duplication mutation of FLT3 blocks myeloid differentiation through suppression of C/EBPalpha expression. Blood, 103, 1883 1890.